What is the current stock price of Myriad Genetics, Inc. (MYGN)?

As of the latest market data, Myriad Genetics, Inc. (MYGN) is trading at $5.08. The stock has seen a gain of 1.60% today.

Does Myriad Genetics, Inc. (MYGN) pay a dividend?

Based on current data, Myriad Genetics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Myriad Genetics, Inc.?

The current market capitalization of Myriad Genetics, Inc. (MYGN) is approximately unavailable.

MYGN

Myriad Genetics, Inc.·Healthcare

5.08

1.600%(+0.08)

Market Closed

5.95

17.126%(+0.87)

After Hours

Last Updated: — ET

52W L: $3.7652W H: $8.59

MYGN NEWS

globenewswire.com

2d ago

Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026

SALT LAKE CITY, April 16, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, announced that it will share six abstracts, including two podium presentations, at the American Association for Cancer Research (AACR) Annual Meeting 2026. "AACR is one of the premier forums for oncology research, and we are excited to share the depth of work underway across our MRD and hereditary cancer programs, including two podium presentations demonstrating the exceptional performance of Precise MRD, Myriad's tumor-informed, ultrasensitive MRD assay," said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics.

globenewswire.com

4d ago

Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan

SALT LAKE CITY, April 14, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the use of the MyChoice® Test for prostate cancer patients as a companion diagnostic for Lynparza® (olaparib). With this approval, clinicians can now order the MyChoice Test to determine homologous recombination deficiency (HRD) status for patients with ovarian cancer, and BRCA1/2 status for breast and prostate cancers.

globenewswire.com

Apr 9

Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting

SALT LAKE CITY, April 09, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces that it will share new data at the Society of Gynecologic Oncology (SGO) Annual Meeting, including two oral presentations and two posters. “Having four abstracts accepted at the prestigious SGO annual meeting underscores the importance of the data we are sharing and our commitment to the cancer care continuum,” said Dale Muzzey, PhD, Chief Scientific Officer, Myriad Genetics.

seekingalpha.com

Mar 31

Myriad Genetics: SOTP Suggests The Company Is Undervalued

Myriad Genetics, Inc. has grown from a mainly Hereditary Cancer business into a broader precision medicine company, but the market still values it at a low multiple because earnings, cash flow, and. The strongest part of the business is still the core Hereditary Cancer franchise, which has shown better resilience than other units through stronger volume trends and steadier operating performance. Even on a conservative sum-of-the-parts basis, the stock appears undervalued, with an estimated value of about $6.05 per share versus the current market price. Followed by portfolio simplification can bring further upside.

zacks.com

Mar 25

Myriad (MYGN) Up 4.1% Since Last Earnings Report: Can It Continue?

Myriad (MYGN) reported earnings 30 days ago. What's next for the stock?

zacks.com

Mar 19

Why Myriad Genetics (MYGN) is a Top Growth Stock for the Long-Term

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Company Profile

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Employees

2,700

IPO Date

1995-10-06

Beta

1.64

Websitemyriad.com↗